Dong-A ST Co., Ltd. (KRX:170900)
South Korea
· Delayed Price · Currency is KRW 44,850
-1,000 (-2.18%)
At close: Mar 28, 2025, 3:30 PM KST
Dong-A ST Revenue
Dong-A ST had revenue of 191.50B KRW in the quarter ending September 30, 2024, with 14.95% growth. This brings the company's revenue in the last twelve months to 700.31B, up 9.92% year-over-year. In the year 2023, Dong-A ST had annual revenue of 663.98B with 4.50% growth.
Revenue (ttm)
700.31B
Revenue Growth
+9.92%
P/S Ratio
0.55
Revenue / Employee
413.67M
Employees
1,687
Market Cap
410.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 663.98B | 28.59B | 4.50% |
| Dec 31, 2022 | 635.39B | 42.16B | 7.11% |
| Dec 31, 2021 | 593.23B | 6.50B | 1.11% |
| Dec 31, 2020 | 586.73B | -25.58B | -4.18% |
| Dec 31, 2019 | 612.31B | 44.88B | 7.91% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |
Dong-A ST News
- 3 months ago - Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA - Financial Post
- 6 months ago - US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Financial Post
- 6 months ago - US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA® - Benzinga